# Potential predictors of COVID-19 disease infection and severity in Egypt

**Authors:** Wedad M. Abdelraheem, Raghda Raouf Shady, Wafaa K. M. Mahdi, Mohamed Ibrahim Bassyouni, Heba S. Kamel, Yosra M. Mousa, Shiamaa F. Kamel, Manal Mohamed Saber, Soha S. Abdelrahim

PMC · DOI: 10.1038/s41598-025-34444-y · 2026-01-29

## TL;DR

This study identifies immune and genetic markers that may help assess the severity of COVID-19 in Egyptian patients.

## Contribution

The study identifies specific immunological and miRNA changes associated with varying severity levels of COVID-19 in Egypt.

## Key findings

- CD4+ and CD8+ T cell counts were reduced in COVID-19 patients, especially in severe cases.
- Serum levels of IL-1β and IL-6 were significantly higher in severe to critical patients.
- miR-146a was decreased and miR-133a was increased in COVID-19 patients compared to healthy controls.

## Abstract

This study aimed to detect the changes in certain immunological parameters and miRNAs in COVID-19 cases with various degrees of disease severity and compare these changes in cases to healthy controls. This study was conducted on 45 COVID‐19 patients and 45 healthy controls. The flow cytometry was conducted to study the number of CD4 + and CD8 + T cells and evaluate the level of the PD-1 marker on their surfaces for all study participants. The determination of IL-1β and IL-6 in serum for all study subjects was done by ELISA test. Relative gene expression quantitation of miR-146a and miR-133a was performed by reverse transcriptase real-time PCR (RT-PCR). The numbers of CD4 + and CD8 + T cells were dramatically reduced in COVID-19 patients, especially in severe to critical patients, with an increase in the CD4 + :CD8 + ratio. T cells from COVID-19 patients had significantly higher levels of the exhausted marker PD-1. Measurement of IL-1β and IL-6 serum levels among cases group showed a highly significant increase in their mean concentration levels in comparison with the control group. Studying the difference in serum levels of IL-1β and IL-6 among different degrees of disease severity showed a significant decrease in their mean concentration levels among the mild to moderate group in comparison with the severe to critical group. The results also showed a significant decrease in miR-146a and a significant increase in miR-133a expression in COVID-19 patients compared to healthy controls. Reduced T cell counts, increased CD4 + :CD8 + ratio, higher levels of the PD-1 marker, elevated serum levels of the pro-inflammatory cytokines, and decreased miR-146a and increased miR-133a gene expressions could be used as potential markers in the assessment of COVID-19 infection and severity.

The online version contains supplementary material available at 10.1038/s41598-025-34444-y.

## Linked entities

- **Genes:** MIR146A (microRNA 146a) [NCBI Gene 406938], MIR133A (microRNA mir-133a) [NCBI Gene 100315053]
- **Proteins:** CD4 (CD4 molecule), CD8A (CD8 subunit alpha), PDCD1 (programmed cell death 1), IL1B (interleukin 1 beta), IL6 (interleukin 6)
- **Diseases:** COVID-19 (MONDO:0100096)

## Full-text entities

- **Genes:** CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, MIR1263 (microRNA 1263) [NCBI Gene 100302148] {aka MIRN1263, hsa-mir-1263}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, F2 (coagulation factor II, thrombin) [NCBI Gene 2147] {aka PT, RPRGL2, THPH1}, PDCD1 (programmed cell death 1) [NCBI Gene 5133] {aka ADMIO4, AIMTBS, CD279, PD-1, PD1, SLEB2}, CAT (catalase) [NCBI Gene 847], FSD1 (fibronectin type III and SPRY domain containing 1) [NCBI Gene 79187] {aka GLFND, MIR1}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, CD4 (CD4 molecule) [NCBI Gene 404704], MIR208B (microRNA 208b) [NCBI Gene 100126336] {aka MIRN208B, mir-208b}, FGB (fibrinogen beta chain) [NCBI Gene 2244] {aka HEL-S-78p}, SNCA (synuclein alpha) [NCBI Gene 6622] {aka NACP, PARK1, PARK4, PD1}, GDE1 (glycerophosphodiester phosphodiesterase 1) [NCBI Gene 51573] {aka 363E6.2, MIR16}, HAVCR2 (hepatitis A virus cellular receptor 2) [NCBI Gene 84868] {aka CD366, HAVcr-2, KIM-3, SPTCL, TIM3, TIMD-3}, CD3E (CD3 epsilon subunit of T-cell receptor complex) [NCBI Gene 397455] {aka CD3}, MIR146A (microRNA 146a) [NCBI Gene 406938] {aka MIRN146, MIRN146A, miR-146a, miRNA146A}, MIR21 (microRNA 21) [NCBI Gene 406991] {aka MIRN21, hsa-mir-21, miR-21, miRNA21}, KLRC1 (killer cell lectin like receptor C1) [NCBI Gene 3821] {aka CD159A, NKG2, NKG2A}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, MIR215 (microRNA 215) [NCBI Gene 406997] {aka MIRN215, miRNA215, mir-215}, MIR499A (microRNA 499a) [NCBI Gene 574501] {aka MIR499, MIRN499, hsa-mir-499a, mir-499a}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}
- **Diseases:** COVID-10 (MESH:D000086382), headache (MESH:D006261), opacities (MESH:D003318), NHL (MESH:D008228), gastrointestinal complications (MESH:D005767), chronic diseases (MESH:D002908), viral infection (MESH:D014777), respiratory disease (MESH:D012140), Chest Diseases (MESH:D002637), immune disorders (MESH:D007154), cough (MESH:D003371), loss of taste (MESH:D000370), acute myocardial infarction (MESH:D009203), fever (MESH:D005334), acute respiratory distress syndrome (MESH:D012128), pneumonia (MESH:D011014), metabolic disorders (MESH:D008659), Lymphopenia (MESH:D008231), inflammation (MESH:D007249), septic shock (MESH:D012772), infected (MESH:D007239), inflammatory drugs (MESH:D000081015), Leukocytosis (MESH:D007964), skin rash (MESH:D005076), immune dysregulation (OMIM:614878), muscle pain (MESH:D063806), ITP (MESH:D016553), sepsis (MESH:D018805), interstitial fibrosis (MESH:D005355), multiple organ failure (MESH:D009102), coagulopathy (MESH:D001778), cancer (MESH:D009369), fatigue (MESH:D005221), Thrombocytopenia (MESH:D013921), critical disease (MESH:D016638), neutrophilia (MESH:C563010), Monocytopenia (OMIM:614172), cardiopulmonary diseases (MESH:D006323), leucopenia (MESH:C536227)
- **Chemicals:** EDTA (MESH:D004492), O2 (MESH:D010100), steroid (MESH:D013256), anti- (-)
- **Species:** Betacoronavirus (genus) [taxon 694002], Mus musculus (house mouse, species) [taxon 10090], Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049], Homo sapiens (human, species) [taxon 9606], Adenoviridae (family) [taxon 10508], Severe acute respiratory syndrome-related coronavirus (no rank) [taxon 694009]

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12855883/full.md

---
Source: https://tomesphere.com/paper/PMC12855883